Basis of Presentation (Tables)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Schedule of Indefinite-Lived Intangible Assets

U.S. Method Patent	13.4 years at acquisition
Web Domain	Indefinite life
Trademark	Indefinite life

Schedule of Revenue Recognition

The Company’s revenues consisted of the following:

	For the Years Ended
	December 31,
	2025		2024
Allergy Diagnostic Kit Sales	$	823,108	$	832,987
Integrated Service Program Revenue		1,121,134		643,211
Immunotherapy Treatment Sales		487,762		409,319
Clinical Study Revenue		133,650		133,650
Subscription Revenue		43,731		54,523
Shipping & Handling		41,670		35,892
Training & Other Revenue		40,686		22,344
Total Revenue	$	2,691,741	$	2,131,926